公开(公告)号：US20240226188A9

公开(公告)日：2024-07-11

申请号：US18269199

申请日：2021-12-21

Applicant: Evelo Biosciences, Inc.

Inventor： Alexander Bank

IPC: A61K35/74 ,  A61K9/48 ,  A61K38/42 ,  C07K14/805 ,  C12N1/20 ,  G01N33/72

CPC classification number: A61K35/74 ,  A61K9/4858 ,  A61K38/42 ,  C07K14/805 ,  C12N1/205 ,  G01N33/721 ,  C12R2001/01

Abstract: Methods and compositions related to pharmaceutical agents, pharmaceutical compositions, and solid dosage forms comprising animal hemoglobin and bacteria or agents of bacterial origin are provided herein.

公开(公告)号：US11850313B2

公开(公告)日：2023-12-26

申请号：US17127965

申请日：2020-12-18

Applicant: The London Health Sciences Centre Research Inc.

Inventor： Alp Sener ,  Smriti Juriasingani

IPC: A01N1/02 ,  A61K31/67 ,  A61K33/04 ,  A61K35/14 ,  A61K38/42 ,  A61L2/00

CPC classification number: A61L2/0088 ,  A01N1/0226 ,  A61K31/67 ,  A61K33/04 ,  A61K35/14 ,  A61K38/42

Abstract: A tissue oxygenation composition comprising (a) an oxygenated solution or a solution containing an oxygen carrier and (b) hydrogen sulfide (H2S). The disclosure also relates to methods of preserving, reperfusing and/or transfusing tissue with a tissue oxygenation composition according to the present disclosure.

公开(公告)号：US11813316B2

公开(公告)日：2023-11-14

申请号：US16717420

申请日：2019-12-17

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services

Inventor： Naoya Uchida ,  John F. Tisdale

IPC: C12N15/867 ,  C12N15/113 ,  C12N15/12 ,  A61K48/00 ,  A61K38/42 ,  C12N15/86 ,  C07K14/805 ,  C12N7/00

CPC classification number: A61K38/42 ,  A61K48/005 ,  C07K14/805 ,  C12N7/00 ,  C12N15/86 ,  C12N2740/16043 ,  C12N2830/008 ,  C12N2830/46

Abstract: The invention is directed to a more efficient lentiviral vector comprising a nucleic acid sequence encoding a human β-globin protein or a human γ-globin protein, which is oriented from 5′ to 3′ relative to the lentiviral genome. The invention also provides a composition and method utilizing the lentiviral vector.

公开(公告)号：US20180000905A1

公开(公告)日：2018-01-04

申请号：US15540661

申请日：2015-12-30

Applicant: Southwest Technologies, Inc.

Inventor： Edward I. STOUT ,  Chandan K. SEN

IPC: A61K38/39 ,  A61K38/42 ,  A61K38/51 ,  A61L26/00

CPC classification number: A61K38/39 ,  A61K38/42 ,  A61K38/51 ,  A61L26/0033 ,  A61L26/008 ,  A61L2400/06 ,  C12Y402/01001 ,  A61K2300/00

Abstract: Methods, compositions, and treatment protocols for treating ischemic wounds and inflammatory conditions in a patient. The treatment protocols comprise or consist of using a modified collagen gel (MCG) to promote healing of ischemic wounds and reduce inflammation at the wound site and in other inflammatory conditions. The modified collagen gel comprises generally a dispersion of collagens in an aqueous matrix comprising water and glycerine, where the amount of Type I collagen is greater than the amount of Type II and Type III collagens in the gel.

公开(公告)号：US20170360706A1

公开(公告)日：2017-12-21

申请号：US15532993

申请日：2015-12-03

Applicant: VINDICO NANOBIOTECHNOLOGY, LLC

Inventor： P. PETER GHOROGHCHIAN

IPC: A61K9/127 ,  A61K38/42 ,  A61K31/404

CPC classification number: A61K9/1273 ,  A61K31/404 ,  A61K31/765 ,  A61K33/26 ,  A61K38/42 ,  A61K45/06 ,  A61K47/34 ,  A61P35/00 ,  A61K2300/00

Abstract: Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM as a result of the nitric oxide sequestration by PEM. Nitric oxide sequestration may cause a reduction in available extracellular nitric oxide in the tumor endothelium, which may prompt a widespread shutdown of vascular flow, hemorrhage, and necrosis. In particular, shutdown of vascular flow may trigger changes in nitric oxide production as well as trigger an acute inflammatory response, which may create reactive nitrogen species that are particularly destructive to the microvasculature. PEM constructs are developed that incorporate large amounts of iron-containing protein, possess high oxygen affinities, and demonstrate delayed nitric oxide binding. Such properties induce selective NME of tumors after extravasation, and will likely enhance the effect of VEGFR TKIs and/or mTOR inhibitors.

公开(公告)号：US20170266285A1

公开(公告)日：2017-09-21

申请号：US15469978

申请日：2017-03-27

Applicant: Vision Global Holdings Ltd.

Inventor： Bing Lou WONG ,  Norman Fung Man WAI ,  Sui Yi KWOK ,  Man Kin WONG ,  Cornelia Wing Yin MAN

IPC: A61K45/06 ,  A61K51/08 ,  A61K49/00 ,  A61K38/42

CPC classification number: A61K45/06 ,  A61K38/42 ,  A61K47/6445 ,  A61K49/0043 ,  A61K49/0056 ,  A61K51/088

Abstract: The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

公开(公告)号：US20170224626A1

公开(公告)日：2017-08-10

申请号：US15016224

申请日：2016-02-04

Applicant: Billion King International Ltd.

Inventor： Bing Lou WONG ,  Sui Yi KWOK

IPC: A61K9/50 ,  A61K47/40 ,  A61K47/20 ,  A61K45/06 ,  A61K47/18 ,  A61K38/42 ,  A61K47/26

CPC classification number: A61K9/5078 ,  A61K9/5026 ,  A61K38/42 ,  A61K45/06 ,  A61K47/40

Abstract: The present invention provides an enteric-coated hemoglobin multiparticulate comprising a core, a hemoglobin formulation coating, an inner or sub-coating, and an enteric coating. The present invention also provides a method of preparing said enteric-coated hemoglobin multiparticulate. The present invention further provides a method for treating various diseases caused by oxygen deficiency comprising administering to a subject said enteric-coated hemoglobin multiparticulate in order to orally deliver the encapsulated hemoglobin-based oxygen carriers to a specific target of said subject in a controlled release manner.

公开(公告)号：US20160375141A1

公开(公告)日：2016-12-29

申请号：US15016220

申请日：2016-02-04

Applicant: Billion King International Ltd.

Inventor： Bing Lou WONG ,  Sui Yi KWOK

IPC: A61K47/36 ,  A61K38/42 ,  A61K9/28 ,  A61K9/19 ,  A61K9/48 ,  A61K9/20 ,  A61K9/51 ,  A61K45/06

CPC classification number: A61K9/4891 ,  A61K9/0095 ,  A61K9/19 ,  A61K9/2095 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/4833 ,  A61K9/5161 ,  A61K38/42 ,  A61K45/06 ,  B82Y5/00

Abstract: A process for making hemoglobin based oxygen carrier (HBOC) containing pharmaceutical composition suitable for oral delivery and the composition formed thereby are described. There are three exemplary composition configurations which include (1) hemoglobin-loaded nanoparticles solution, (2) enteric-coated hemoglobin capsules and (3) enteric-coated hemoglobin tablets. To facilitate the bioavailability and bio-compatibility of hemoglobin, intestinal absorption enhancers are added in each of the HBOC formulations. Protective layers ensure delivery of an intact hemoglobin structure in intestinal tract without degradation in the stomach. The HBOC formulations may be used for preventive or immediate treatment of high altitude syndrome (HAS) or for treatment of hypoxic conditions including blood loss, anemia, hypoxic cancerous tissue, and other oxygen-deprivation disorders. In addition to delivering oxygen, the heme group of hemoglobin from HBOC formulations can provide heme iron to the human body to aid in the production of more red blood cells. The presently claimed invention provides improved hemoglobin formulations for forming nanoparticles with improved properties via polyelectrolyte complexation and for lyophilization to form mixture powder or particles with improved properties.

Abstract translation: 描述了制备含有适于口服输送的药物组合物的血红蛋白基氧载体（HBOC）的方法和由此形成的组合物。 有三种示例性组合构型，其包括（1）载有血红蛋白的纳米颗粒溶液，（2）肠溶包衣血红蛋白胶囊和（3）肠溶包衣血红蛋白片剂。 为了促进血红蛋白的生物利用度和生物相容性，在每种HBOC制剂中加入肠吸收增强剂。 保护层确保在肠道中输送完整的血红蛋白结构，而不会在胃中降解。 HBOC制剂可用于预防或立即治疗高原综合征（HAS）或用于治疗缺氧症状，包括失血，贫血，缺氧性癌组织和其他缺氧障碍。 除了提供氧气外，来自HBOC配方的血红素血红素组可以向人体提供血红素铁，以帮助生产更多的红细胞。 本发明提供的改进的血红蛋白制剂用于通过聚电解质复合形成具有改进性质的纳米颗粒，并且用于冻干以形成具有改进性质的混合物粉末或颗粒。

公开(公告)号：US09486508B2

公开(公告)日：2016-11-08

申请号：US14930396

申请日：2015-11-02

Applicant: Washington University

Inventor： Gregory M. Lanza ,  Dipanjan Pan ,  Allan Doctor ,  Philip C. Spinella

IPC: A61K31/70 ,  A61K9/16 ,  A61K49/00 ,  A61K38/41 ,  A61K31/519 ,  A61K31/44 ,  A61K31/355 ,  B23B5/16 ,  A61K38/42 ,  A61K9/00 ,  A61K9/107 ,  A61K38/06 ,  A61K9/51 ,  B82Y5/00

CPC classification number: A01N1/0226 ,  A61K9/0026 ,  A61K9/107 ,  A61K9/51 ,  A61K38/063 ,  A61K38/42 ,  B82Y5/00 ,  A61K2300/00

Abstract: The present disclosure provides oxygen-carrying nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to carry oxygen in blood.

Abstract translation: 本公开内容提供了含氧纳米颗粒，制备纳米颗粒的方法以及使用纳米颗粒在血液中携带氧气的方法。

公开(公告)号：US20160312226A1

公开(公告)日：2016-10-27

申请号：US15105925

申请日：2014-12-18

Applicant: Kelvin LEE ,  Abraham LENHOFF ,  Kristen VALENTE ,  Nick LEVY ,  Yatin GOKARN

Inventor： Kelvin LEE ,  Abraham LENHOFF ,  Kristen VALENTE ,  Nick LEVY ,  Yatin GOKARN

IPC: C12N15/113 ,  A61K38/39 ,  A61K38/17 ,  A61K38/44 ,  C12P21/00 ,  A61K38/48 ,  A61K38/45 ,  A61K38/42 ,  A61K47/26 ,  C07K16/00 ,  A61K38/52

CPC classification number: C12N15/1137 ,  A61K38/1709 ,  A61K38/1741 ,  A61K38/1761 ,  A61K38/1774 ,  A61K38/39 ,  A61K38/42 ,  A61K38/44 ,  A61K38/443 ,  A61K38/45 ,  A61K38/4813 ,  A61K38/482 ,  A61K38/488 ,  A61K38/52 ,  A61K47/26 ,  C07K16/00 ,  C12N9/20 ,  C12N2310/10 ,  C12N2310/14 ,  C12N2310/20 ,  C12P21/005 ,  C12P21/02 ,  C12Y104/03013 ,  C12Y111/01015 ,  C12Y205/01018 ,  C12Y207/04006 ,  C12Y207/11001 ,  C12Y301/01034 ,  C12Y304/16005 ,  C12Y304/21 ,  C12Y304/23005 ,  C12Y502/01008 ,  C12Y503/04001

Abstract: The invention relates a method for producing a stable recombinant protein, comprising growing a non-naturally occurring host cell in a culture medium to produce a recombinant protein, and making a composition comprising the recombinant protein and a polysorbate. The production of endogenous lipoprotein lipase by the host cell is reduced. The endogenous lipoprotein lipase is present in the composition in a small amount, and is capable of degrading the polysorbate. The invention also relates to the relevant host cells and compositions, and preparation thereof.

Abstract translation: 本发明涉及一种生产稳定重组蛋白的方法，包括在培养基中培养非天然存在的宿主细胞以产生重组蛋白，以及制备包含重组蛋白和聚山梨酯的组合物。 由宿主细胞产生的内源性脂蛋白脂肪酶降低。 内源性脂蛋白脂肪酶以少量存在于组合物中，并且能够降解聚山梨醇酯。 本发明还涉及相关宿主细胞和组合物及其制备。